复发高级别胶质瘤的挽救性再照射及与贝伐珠单抗单药治疗的比较
该研究分析了2010至2014年在Dana-Farber癌症研究所和布莱根妇女医院接受再照射的复发高级别胶质瘤患者67例,以及与接受贝伐珠单抗单药治疗的177例患者进行比较。再照射后中位无进展生存期和总生存期分别为4.8个月和10.7个月,未观察到超过2级的早期或晚期毒性。再照射后总生存期与剂量/分割方案无关,与贝伐珠单抗单药相比总生存期有非显著延长(HR 0.80;95%CI,0.53-1.23;P=.31)。
要点
- 再照射后中位无进展生存期4.8个月,中位总生存期10.7个月。
- 再照射前进展次数和新发脑部复发位置与总生存期相关,剂量/分割方案无关。
- 与贝伐珠单抗单药相比,再照射总生存期非显著延长(HR 0.80;95%CI,0.53-1.23)。
核心结论
- 复发高级别胶质瘤再照射后的生存似乎与剂量/分割方案无关,与贝伐珠单抗单药相比具有有利趋势。
研究设计与样本
- 分析2010至2014年在Dana-Farber癌症研究所和布莱根妇女医院接受再照射的复发高级别胶质瘤患者67例,以及接受贝伐珠单抗单药治疗的患者177例。
- 采用Cox比例风险模型分析与总生存期相关的因素,采用倾向性评分模型比较再照射与贝伐珠单抗单药治疗后的生存。
主要发现
- 从初诊至再照射的中位时间为31.4个月。
- 最常用的再照射剂量/分割方案为6 Gy×5(36%)、3.5 Gy×10(21%)、2.67 Gy×15(15%)和18-20 Gy×1(15%)。
- 未观察到超过2级的早期或晚期毒性。
- 再照射后中位无进展生存期和总生存期分别为4.8个月和10.7个月。
- 再照射前进展次数(校正风险比[AHR] 1.6;95%CI,1.1-2.3;p=.007)和新发脑部位置复发(对比仅局部复发;AHR 7.4;95%CI,2.4-23.1;p<.001)与总生存期相关;剂量/分割方案与总生存期无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While salvage re-irradiation is often used for recurrent high-grade glioma (HGG), there have been few comparisons between various re-radiation dose/fractionation schedules or with bevacizumab alone. We analyzed patients with recurrent HGG who received re-irradiation at Dana-Farber Cancer Institute and Brigham and Women's Hospital from 2010 to 2014 (n = 67), as well as those who received bevacizumab alone (n = 177). Cox proportional hazards modeling was used to examine factors associated with overall survival (OS). Propensity score modeling was used to compare survival after re-irradiation vs. bevacizumab alone. Median time from initial diagnosis to re-irradiation was 31.4 months. The most common re-irradiation dose/fractionations used were 6 Gy × 5 (36%), 3.5 Gy × 10 (21%), 2.67 Gy × 15 (15%), and 18-20 Gy × 1 (15%). No early or late toxicities >grade 2 were observed. Median PFS and OS after re-irradiation were 4.8 and 10.7 months, respectively. Number of progressions prior to re-irradiation (adjusted hazard ratio [AHR] 1.6; 95% CI, 1.1-2.3; p = .007), and recurrence in a new brain location (vs. local-only; AHR 7.4; 95% CI, 2.4-23.1; p < .001) were associated with OS; dose/fractionation was not. Compared with bevacizumab alone, re-irradiated patients had a non-significant increase in OS (HR 0.80; 95% CI, 0.53-1.23; P = .31). Among patients with a local-only recurrence, there was a trend towards longer median OS after re-irradiation compared to bevacizumab alone (12.4 vs. 8.0 months; p = .12). Survival after re-irradiation for recurrent HGG appears independent of dose/fractionation and compares favorably with bevacizumab alone.
引用
- Arvold ND, Shi DD, Aizer AA, et al. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017. PMID: 28975467. doi:10.1007/s11060-017-2611-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。